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ABSTRACT
BACKGROUND: Kanglaite (KLT) is a botanically sourced, molecularly targeted
agent that is prepared as a microemulsion for IV use. The active substance is extracted
from the herb Semen coicis.
OBJECTIVE: The aim of this study was to evaluate the effeCtiveness and tolerabili-
ty of KLT injection in patients with primary non-small cell lung cancer (NSCLC).
METHODS: We electronically searched the literature of the China National
Knowledge Infrastructure (Chinese language, 1979-March 2008), CBMdisc (Chinese,
1978-March 2008), The Cochrane Library (English, Issue 4, 2007), MEDLINE
(English, 1966-March 2008), and EMBASE (English, 1984-March 2008), and
manually searched 20 Chinese-language oncology journals to identify randomized
controlled trials (RCTs) of KLT injection plus chemotherapy versus chemotherapy
alone, regardless of their having been published or not, blinding, duration of treat-
ment, or duration of follow-up. The quality of the included trials was assessed using the
method recommended by The Cochrane Collaboration. The studies were assigned to
1 of the following 3 categories: A = all quality criteria met, low risk of bias; B = ;:0: 1
of the quality criteria only partially met, moderate risk of bias; or C = ;:0:1 of the quali-
ty criteria not met, high risk of bias. If heterogeneity existed among subgroups, then
overall results were calculated based on a random-effects model; otherwise, a fixed-
effects model was used.
RESULTS: Electronic database searches yielded 596 citations. A title review
eliminated 377 manuscripts; 219 citations were marked for further evaluation. Finally,
we identified 26 trials that met the inclusion and exclusion criteria. The 26 RCTs
included in this meta-analysis included 2209 patients with NSCLC; no study was
graded A, 9 were graded B, and 17 were graded C. The sample size ofeach trial varied
from 40 to 305 patients; none of the trials had precalculated sample sizes. Pooled
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analyses performed using both fixed- and random-effects models revealed that compared
with chemotherapy alone, KLT injection plus chemotherapy improved the response
rate (relative risk [RR}, 1.34; 95% CI, 1.19-1.51 and RR, 1.35; 95% CI, 1.20-1.51,
respectively) and quality of life as measured by an increase ;::0:10 points in the Karnof-
sky Performance Status score (RR, 2.05; 95% CI, 1.60-2.64). KLT injection plus
chemotherapy was associated with improvement in the symptoms of cough, dyspnea,
chest pain, fatigue, and anorexia. KLT injection plus chemotherapy was also associated
with significant reduction in the incidence of the following adverse events (AEs)
based on the fixed and random effects models, respectively: grade II to IV leukopenia
(RR, 0.29; 95% CI, 0.22-0.39 and RR, 0.33; 95% CI, 0.22-0.48), anemia (RR, 0.54;
95% CI, 0.42-0.70 and RR, 0.55; 95% CI, 0.40-0.76), thrombocytopenia (RR, 0.39;
95% CI, 0.21-0.71 and RR, 0.40; 95% CI, 0.21-0.78), nausea and vomiting (RR,
0.44; 95% CI, 0.34-0.57 and RR, 0.44; 95% CI, 0.35-0.57), phlebitis (RR, 3.44;
95% CI, 1.30-9.15 and RR, 3.38; 95% CI, 1.28-8.89), and hepatic dysfunction (RR,
0.44; 95% CI, 0.15-1.35 and RR, 0.44; 95% CI, 0.24-0.81).
CONCLUSION: This meta-analysis found that KLT injection in combination
with chemotherapy was associated with improved response rate, quality of life, and
symptoms, and a reduced incidence of AEs compared with chemotherapy alone in
patients with NSCLC. These findings should be viewed with caution because of the
low quality of the included trials. (Curr Ther Res Clin Exp. 2008;69:381-411) © 2008
Excerpta Medica Inc.
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INTRODUCTION
Lung cancer is the leading cause of cancer-related mortality in the United States. l In
2005, 172,570 new cases of lung cancer were diagnosed and 163,510 resulted in
death. When lung cancer patients are found unsuitable for surgery at diagnosis, che-
motherapy remains a treatment option. Histologically, ~80% of these tumors are of
the non-small cell type, including adenocarcinomas and squamous cell and large cell
carcinomas. Non-small cell lung cancer (NSCLC) is the main cause of cancer-related
deaths. l In advanced-stage NSCLC, chemotherapy prolongs survival and improves
patient quality of life, but its effectiveness is not completely satisfactory.
Kanglaite (KLT) (Zhejiang Kanglaite Group Co. Ltd., Hangzhou, China) is a
botanically sourced, molecularly targeted agent that is prepared as a microemulsion
for IV use. The active substance is extracted from the herb Semen micis. It is used in
combination with chemotherapy to minimize toxic reactions and enhance the effect
of chemotherapy. In 1995, KLT patent certificates were granted in China. In August
1997, Phase III clinical trials were completed and KLT was officially launched
in China after final approval from the Ministry of Public Health. 2 Since 1997,
>500,000 cancer patients in >2000 large- and medium-sized hospitals in China
have been treated with KLT.
A Semen coicis extract was found to suppress the growth of squamous lung cancer
cells. 3 KLT decreased the number of G21M phase cells, suppressed the proliferation of
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cancer cells, and induced apoptosis of cancer cells, actions that constitute an important
mechanism of the antitumor action of KiT.4 KiT was found to be effective in reversing
multiple-drug resistance of cells and increasing the sensitivity of mouse cancer cells to
chemotherapeutic agents. s KiT injection might have a direct effect on cancer cell death
and improvement of patients' immune function, symptoms, and quality of life.6
A Cochrane protocol focused on symptom palliation of patients with lung cancer
rather than effectivenessJ To date, no systematic review or meta-analysis of the ef-
fectiveness of KLT injection in patients with primary NSCLC has been done.
The aim of this meta-analysis was to evaluate the effectiveness and tolerability of KiT
injection plus chemotherapy versus chemotherapy alone for patients with NSCLC.
MATERIALS AND METHODS
STUDY DESIGN
Only randomized controlled trials (RCTs) were eligible for this review; blinding,
language, published or not, duration of treatment, and the duration of follow-up were
not considered. Uncontrolled and observational studies were excluded.
PATIENTS
Patients were eligible for the study if they had primary NSCLC that was con-
firmed cytologically, pathologically, or by computed tomography or if they had
inoperable stage II to IV cancer or stage II cancer and had refused surgery. Patients
with a Karnofsky Performance Status (KPS) scores 250 and an expected survival
time of 23 months who were aged 218 years were also eligible. Finally, patients not
treated with chemotherapy or radiotherapy who had not participated in a trial for
22 months were also eligible.
Patients were excluded from the study if they had liver, brain, or bone metastasis
(although asymptomatic patients were eligible); severe heart, hepatic, or renal disease;
markedly abnormal blood biochemistry findings; or hepatic or renal dysfunction. Pa-
tients who had just undergone surgery or radiotherapy treatment were also excluded.
INTERVENTIONS
The trial groups received KLT injection plus chemotherapy and the control groups
received chemotherapy alone, regardless of the duration of treatment or follow-up. The
basic treatment in both trial and control groups was identical except for KiT injection.
OUTCOME MEASURES
Mortality Rate
Mortality rate at the end of treatment or follow-up was calculated.
Response Rate
Response Evaluation Criteria in Solid Tumors, formulated by the World Health
Organization (WHO), was used to evaluate the response rate. 9 Based on the degree of
tumor absorption, response was classified as follows: (1) complete response (CR) = chest
radiograph or computed tomography and/or fiber bronchoscopy revealed complete
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absorption of the lesion; (2) partial response (PR) = lesion decreased by ;:::50%
but ~99%; (3) no change = lesion decreased by <50% or increased by <25%; and
(4) progressive disease = lesion increased by >25% after treatment. Based on the com-
parison of chest radiograph or computed tomography before and after treatment, the
response rate was defined as CR + PR.8
Quality-of-Life Improvement
Quality of life before and after treatment was assessed using the KPS. Only data for
patients whose KPS scores improved by ;:::10 points (the minimal clinically significant
difference) after treatment were extracted.
Symptom Improvement
The percentage of patients exhibiting improvement in the symptoms of cough, he-
moptysis, chest pain, fever, fatigue, and anorexia was assessed. We also calculated the
percentage of patients whose symptoms resolved completely. Improvement in symptoms
was assessed according to the information provided in each included study.
Specifically, for the pooled analysis of the trials in which symptom improvement
was reported, symptoms were scored according to their degree of severity (ie, grades 1-
III). For the symptoms of cough, chest pain, and dyspnea, grade I was assigned when
the symptoms did not influence daily life, and grade III was assigned when the symp-
toms were severe, with a marked influence on daily life; symptoms between grade I
and III were assigned grade II. For hemoptysis, sputum with blood was assigned grade
I, sputum with blood clots or sputum with ~ 10 mUd of blood was assigned grade II,
and extremely bloody sputum or sputum with> 10 mUd of blood was assigned grade
III. A reduction of more than two thirds in the total score of clinical symptoms was
considered improvement, a reduction of no more than two thirds but greater than one
third was considered partial improvement, and an unchanged total score or a reduc-
tion of no more than one third was considered stable disease.
ADVERSE EVENTS
Adverse events (AEs) were evaluated at the completion of treatment and included
bone marrow suppression (leukopenia, anemia, and thrombocytopenia), nausea and
vomiting, phlebitis, hepatic dysfunction, and renal dysfunction. According to the
WHO grading criteria for acute and subacute toxicity of anticancer dtugs,1O we only
calculated AEs of grades II to IV. If patients withdrew from the study due to an AE,
we also included these AEs.
LITERATURE COLLECTION
We electronically searched literature of the China Narional Knowledge Infrastructure
(Chinese language, 1979-March 2008), CBMdisc (Chinese, 1978-March 2008), The
Cochrane Library (English, Issue 4, 2007), MEDLINE (English, 1966-March 2008),
and EMBASE (English, 1984-March 2008). The reference lists of relevant trials were
obtained. We also collected data from ongoing trials documented in Current Controlled
Trials (www.controlled-trials.com) and Clinical Trials (www.clinicaltrials.gov). In ad-
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dition, we manually searched the following 20 Chinese oncology journals up to March
2008: Chinese Journal of Lung Cancer (l998-March 2008), Chinese-German Journal of
Clinical Oncology (l984-March 2008), Chinese Journal of Cancer Research (1989-March
2008), Journal of Practical Oncology (1987-March 2008), Journal of Modern Oncology
(1993-March 2008), Tumor (l981-March 2008), Journal of Oncology (l995-March
2008), Chinese Journal of Cancer (l987-March 2008), Chinese Clinical Oncology
(1985-March 2008),Journal ofPractical Oncology (l986-March 2008), Bulletin ofChi-
nese Cancer (1992-March 2008), Chinese Journal of Clinical Oncology and Rehabilitation
(1994-March 2008), Chinese Journal of Cancer Prevention and Treatment (1994-March
2008), Cancer Research on Prevention and Treatment (197 3-March 2008), Oncology Progress
(2003-March 2008), Journal of International Oncology (1974-March 2008), Practical
Journal of Cancer (1985-March 2008), Sichuan Journal of Cancer Control (l973-March
2008), ChineseJournal ofOncology (1979-March 2008), and ChineseJournal of Integrated
Traditional and Western Medicine (l981-March 2008).
QUALITY ASSESSMENT AND DATA EXTRACTION
Trial Selection
To select eligible studies, one author (X.i.) independently reviewed the title, ab-
stract, and key words of every retrieved record, and another author (G.W.) checked the
results. Full-text articles were retrieved for futther assessment if the information avail-
able suggested that the study: (1) included patients with NSCLC; (2) compared KLT
injection plus chemotherapy with chemotherapy alone; (3) randomly assigned patients
to the comparison groups; and (4) included the outcome measutes listed previously.
Differences were resolved by discussion.
Quality Assessment
The quality of the trials was assessed according to the Cochrane Collaboration's
criteria11: (1) minimization of selection bias (ie, were the randomization procedure
and the allocation concealment adequate); (2) minimization of performance bias (ie,
were the patients who received treatment and people who administered the treatment
blinded to the interventions); (3) minimization of attrition bias (ie, were withdrawals
and dropouts completely described and was the analysis based on intent to treat
[ITT}); and (4) minimization of detection bias (ie, were outcome assessors blinded to
the interventions). Based on these criteria, the studies were broadly subdivided into
the following 3 categories: A = all quality criteria met, low risk of bias; B = :2:1 of the
quality criteria only partially met, moderate risk of bias; and C = :2: 1 criteria not met,
high risk of bias.
Each trial was assessed independently by one author (X.i.) and was checked by
another author (G.W.). Differences were resolved by discussion.
Data Extraction
Data from each included trial were extracted independently by one author (X.L.)
and checked by another author (G.W.) using a standard extraction form. The form
included the following items:
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• General informarion: published/unpublished; language; aurhors; article ritle; journal
title, year, volume, issue, and page numbers; and funding source;
• Trial design: predetermined sample size, generation of randomization sequence, al-
location concealment method, blinding of information, statistical methods, and
attrition;
• Participants: diagnostic criteria, total number of patients and number of patients in
the comparison groups, baseline characteristics (eg, age, gender), inclusion criteria,
exclusion criteria, and study settings;
• Intervention: type of chemotherapy regimen, duration, time, and dose;
co-intervention; control; withdrawals, dropouts, and lost to follow-up; and
• Outcome: outcomes at the end of treatment.
The number and type of AEs were also extracted. If the aforementioned data were
not available in the trial report, further information was sought by corresponding
with the original principal investigator.
Data Analysis
Data were analyzed using MetaView 4.2.8 in Review Manager 4.2 (Cochrane
collaboration, Oxford, United Kingdom). Meta-analysis was conducted by pool-
ing the different chemotherapy regimens combined with KLT injection and com-
paring these with chemotherapy regimens alone for an overall analysis; however,
the analysis was divided according to subgroups that were formed based on che-
motherapy regimens. Sensitivity analyses were conducted by excluding low-
quality trials. Analyses were conducted using the ITT principle when possible.
Relative risk (RR) was used to analyze dichotomous data. If heterogeneity existed
among subgroups, then overall results were calculated based on the random effect
model; otherwise, the fixed effect model was used. The random effect model was
also used to check whether its use might change the direction of the results in cases
where heterogeneity was not tested. Heterogeneity was tested using the z score
and X2 , and P < 0.1 was considered statistically significant.
RESULTS
Electronic database searches yielded 596 citations. A title review eliminated
377 manuscripts; 219 citations were marked for further evaluation. Finally, we
identified 26 trials l2- 37 that met the inclusion and exclusion criteria. All of the
included studies were published in China. A diagram of the meta-analysis is
shown in Figure 1.
CHARACTERISTICS OF THE INCLUDED TRIALS
All of the included trials met the inclusion criteria. The baseline characteristics of
the trial and control groups in the included trials were comparable. All the patients
in the included trials had NSCLC that was confirmed cytologically or
pathologically.
Interventions and outcome measures used in the included trials are listed 1D
Table 1. 12- 37 No trial reported the outcome measure of mortality.
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Potentially relevant RCTs identified and
screened for retrieval
(N =219)
Trials that were not RCTs
(n =176)
RCTs retrieved for more
detailed evaluation
(n =43)
RCTs excluded (n =17)
Interventions did not meet the inclusion criteria (7)
Participants did not meet the inclusion criteria (4)
Duplicate publications (3)
Quasi-RCTs (2)
Outcome measures did not meet inclusion criteria (1)
Potentially appropriate RCTs included
in the meta-analysis
(n =26)
RCTs excluded from the meta-analysis
(n =0)
RCTs included in the meta-analysis
(n =26)
RCTs withdrawn
(n =0)
RCTs with usable information, by outcome
(n =26)
Figure 1. Flow diagram of the meta-analysis. ReTs = randomized controlled trials.
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Table I. Characteristics of the included trials (N = 26). :IIIII
Z
Interventions ~-t
No. of Cases, Duration, J:
III
Reference Trial/Control Trial Group Control Group Outcome Measures d :II
l>
'lI
Piao et al12 214/91 KLT + MVP or EP MVP or EP Response rate, KPS score improved 42 IIIc
~10 points, symptom improvement ~ii
Chu et al13 40/32 KLT + MVP MVP Response rate, anemia 28 :u
III
Li and Wang14 34/30 KLT + MVP MVP Response rate, KPS score improved 14 1/1III
~10 points, gastrointestinal reaction, hepatic l>
:II
and renal dysfunction n
J:
Yang et al15 28/29 KLT + NP NP Response rate, KPS score improved ~10 points 14
Chen et al16 28/27 KLT + NP NP Response rate, KPS score improved 14
~10 points, leukopenia
Tang17 20/22 KLT + HEP HEP Response rate, KPS score improved 14
~10 points, bone marrow suppression,
gastrointestinal tract reaction, phlebitis
Xie et al18 43/44 KLT + NP NP KPS score improved ~10 points 60
Liu et al19 131/111 KLT + MAP or MVP MAP or MVP Response rate, KPS score improved 42
~10 points, symptom improvement
Lin et al20 39/41 KLT + CAP CAP Response rate, KPS score improved ~10 points, 42
bone marrow suppression, gastrointestinal
reaction, phlebitis, hepatic and
renal dysfunction
Lian et al21 50/50 KLT + GP GP Response rate, gastrointestinal tract 10
reaction, hepatic and renal dysfunction
Deng et al22 21/22 KLT + GP GP Response rate, KPS score improved ~10 points, 21
bone marrow suppression, gastrointestinal
reaction, phlebitis, hepatic and renal dysfunction
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Table I (continued).
Interventions
No. of Cases, Duration,
Reference Trial/Control Trial Group Control Group Outcome Measures d
LU23 62/51 KLT + NP or GP NP or GP Response rate, KPS score improved 20-45
210 points, bone marrow suppression,
gastrointestinal reaction
Lv et al24 30/30 KLT + NP NP Response rate, KPS score improved 21
210 points
Wu et al25 39/44 KLT + NP NP Response rate 42
Wu et al26 21/19 KLT + EP EP Response rate, KPS score improved 10
210 points, bone marrow suppression
Huang et al 27 53/33 KLT + EP EP Response rate, KPS score improved 42-63
210 points, bone marrow suppression,
gastrointestinal reaction, symptom improvement
Li et al28 36/36 KLT + NP NP Response rate, KPS score improved 21
210 points, bone marrow suppression,
gastrointestinal reaction
Li et al29 20/20 KLT + NP NP Response rate, bone marrow suppression, 42
phlebitis
Liu et al30 32/32 KLT + CEP CEP Bone marrow suppression, gastrointestinal 56
reaction
Chen31 30/34 KLT + MVP MVP Response rate, KPS score improved 20
210 points
Song et al32 26/21 KLT + CAP CAP KPS score improved 210 points 42
Wang and Zhang33 39/41 KLT + NP NP Response rate, bone marrow suppression, 42
gastrointestinal reaction, phlebitis,
renal dysfunction
An and Yuan34 48/48 KLT + NP NP Response rate, symptom improvement 10 ?<
~
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Table I (continued).
Interventions
No. of Cases,
Reference Trial/Control Trial Group Control Group
Ju et al35 48/48 KLT + MVP MVP
Zhong et al36 22/26 KLT + NIC NIC
Wang et al37 42/38 KLT + MVP/NP/TP MVP/NP/TP
Outcome Measures
Response rate
KPS score improved ~10 points, symptom
improvement
KPS score improved ~10 points
Duration,
d
42
Unclear
10
n
c:
:l:l
:l:l
III
Z
-t
-l
:I
III
:l:l
l>
"IIIc:
-t
ii
:u
III
III
III
l>
:l:l
n
:I
KLT = kanglaite; MVP = mitomycin + vindesine + cisplatin; EP = cisplatin + etoposide (VP-16); KPS = Karnofsky Performance Status; NP = vinorelbine +
cisplatin; HEP = hydroxycamptothecin + VP-16 + cisplatin; MAP = mitomycin + adriamycin + cisplatin; CAP = cyclophosphamide + adriamycin + cisplat-
in; GP = gemcitabine hydrochloride + cisplatin; CEP = cyclophosphamide + epirubicin + cisplatin; NIC = vinorelbine + ifosfamide + cisplatin; TP =
thymidine phosphorylase.
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QUALITY OF THE INCLUDED TRIALS
The quality of 17 trials was rated C, 9 trials I2 ,13,18-22,24,35 were rated B, and no trial
was rated A. Randomization sequences were generated using a computer in 2 tri-
als,12,13 a random digital table in 4 trials,18,20,22,35 and by drawing lots in 4 tri-
als. 19,21,24,29 Four trials reported double blinding,12,19,22,35 while 5 trials reported
single blinding .13,18,20,21,25 We obtained randomization details of the trials conducted
by Piao et aI12 and Chu et aP3 from Zhejiang Kanglaite Group Co. Ltd. We requested
additional information about randomization from the aurhors of all the included tri-
als, and obtained randomization details from the authors of 5 trials. 2o- 22 ,24,29 The
details are listed in Table II.12-37
META-ANALYSIS RESULTS
Response Rate
The details of the response rates are shown in Figure 2. Response rate was used as
an outcome measure in 22 trials I2- 17,19-31,33-35 (Table I). Heterogeneity was not de-
tected among the subgroups (P = 0.48). Pooled analysis of 9 subgroups revealed that
compared with chemotherapy alone, KLT injection plus chemotherapy improved the
response rate using both fixed (RR, 1.34; 95% CI, 1.19-1.51) and random effect
models (RR, 1.35; 95% CI, 1.20-1.51). Grade C trials were excluded from the sensi-
tivity analysis. The results of the sensitivity analysis were consistent between the fixed
(RR, 1.29; 95% CI, 1.07-1.55) and random effect models (RR, 1.33; 95% CI,
1.05-1.68).
A subgroup analysis of 5 trials I2,14,26,31,35 suggested that a regimen of KLT injec-
tion plus chemotherapy with a regimen of mitomycin with vindesine and cisplatin
(MVP) was associated with greater improvement in the response rate (RR, 1.76; 95%
CI, 1.34-2.31) than chemotherapy alone.
Another subgroup analysis of 2 trials21 ,22 found that compared with chemotherapy
alone, KLT injection plus chemotherapy with gemcitabine hydrochloride plus cisplat-
in (GP) was associated with greater improvement in the response rate (RR, 1.75; 95%
CI, 1.16-2.64).
Subgroup analysis of 8 trials I5 ,16,24,25,28,29,33,34 found that compared with chemo-
therapy with vinorelbine plus cisplatin (NP), KLT injection plus NP was associated
with greater improvement in the response rate (RR, 1.30; 95% CI, 1.07-1.59).
The improvement in the response rates (Figure 2) with KLT injection plus chemo-
therapy was not greater than that associated with chemotherapy alone in the following
regimens: hydroxycamptothecin + etoposide (VP-16) + cisplatin (HEP); cyclophos-
phamide + adriamycin + cisplatin (CAP); GP/NP; MVP/cisplatin + VP-16 (EP);
mitomycin + adriamycin + cisplatin (MAP)/MVP; cyclophosphamide + epirubicin +
cisplatin (CEP); and EP.
Analyses of the MVP, GP, and NP chemotherapy regimen subgroups found a sta-
tistical difference between KLT injection plus chemotherapy and chemotherapy alone.
Each subgroup included data from > 2 trials, with a sample size ranging from 71 to
275. Meanwhile, the analyses of the other 7 subgroups did not show a statistical dif-
ference between the 2 groups with regard to the response rate. Each subgroup in-
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I\) Table II. Quality assessment of the included trials (N =26). ;:a;:a
III
Z
Random -4
Sequence Allocation Lost to Follow-UP/ Study oj:t
Reference Generation Concealment Blinding Duration of Follow-Up ITT Qualityll' III;:a
l>
Piao et al12 Computer Unclear Double Number lost to follow-up and reason for loss Yes B "III
of follow-up were reported/19 months c:-4
Chu et al13 Computer Unclear Single Number lost to follow-up was reported/19 months Yes B n
:II
Li and Wang14 Unclear Unclear Unclear No loss of follow-up/35 months Yes C III(II
Yang et al15 Unclear Unclear Unclear Number lost to follow-up was reported/36 months No C IIIl>
Chen et al16 Unclear Unclear Unclear No loss of follow-up/60 months Yes C
;:a
n
:t
Tang17 Unclear Unclear Unclear No loss of follow-up/30 months Yes C
Xie et al18 Random Adequate Single 6 Patients lost to follow-up/12 months No B
digital table
Liu et al19 Drawing lots Envelope Double Number lost to follow-up and reason for loss Yes B
of follow-up were reported/16 months
Lin et al20 Random Adequate Single No loss of follow-up/52 months Yes B
digital table
Lian et al21 Drawing lots Envelope Single No loss of follow-up/17 months Yes B
Deng et al22 Random Adequate Double No loss of follow-up/36 months Yes B
digital table
Lu23 Unclear Unclear Unclear No loss of follow-up/30 months Yes C
Lv et al24 Drawing lots Adequate Single No loss of follow-up/34 months Yes B
Wu et al25 Unclear Unclear Unclear No loss of follow-up/60 months Yes C
Wu et al 26 Unclear Unclear Unclear No loss of follow-up/24 months Yes C
Huang et al 27 Unclear Unclear Unclear No loss of follow-up/2.8 to 6.3 months Yes C
Li et al28 Unclear Unclear Unclear No loss of follow-up/42 months Yes C
Li et al29 Drawing lots Inadequate No blinding No loss of follow-up/24 months Yes C
Liu et al30 Unclear Unclear Unclear No loss of follow-up/unclear Yes C
Chen31 Unclear Unclear Unclear No loss of follow-up/32 months Yes C
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Table II (continued).
Random
Sequence Allocation Lost to Follow-Up/ Study
Reference Generation Concealment Blinding Duration of Follow-Up ITT Qualityl1*
Song et al32 Unclear Unclear Unclear No loss of follow-up/117 months Yes C
Wang and Zhang33 Unclear Unclear Unclear No loss of follow-up/53 months Yes C
An and Yuan34 Unclear Unclear Unclear No loss of follow-up/24 months Yes C
Ju et al35 Random Adequate Double Number and reason for loss of follow-up were No B
digital table reported/18 months
Zhong et al36 Unclear Unclear Unclear No loss of follow-up/unclear Yes C
Wang et al37 Unclear Unclear Unclear No loss of follow-up/20 months Yes C
In = intention-to-treat.
*A = all quality criteria met, low risk of bias; B = ~1 of the quality criteria only partially met, moderate risk of bias; C = ~1 of the quality criteria not
met, high risk of bias.
><
C
c:
III
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MVP + KLT vs MVP
Ju et al35 16/48 12/48 4.08 1.33 (0.71-2.51) B
Wu et aj26 9/21 5/19 1.78 1.63 (0.66-4.01) C
Chen3l 24/30 16/34 - 5.10 1.70 (1.14-2.53) CLi and Wang" 19/34 9/30 3.25 1.86 (1.00-3.47) C
Piao et al" 18/40 7/40 • 2.38 2.57 (1.21-5.47) B
Subtotal (95% CI) 173 171 • 16.58 1.76 (1.34-2.31)Total events: 86 (KLT), 49 (Chemotherapy)
Test for heterogeneity: X' =1.80, df =4 (P =0.77), /' =0%
Test for overall effect: z =4.06 (P < 0.001)
GP + KLT vs GP
Lian et al" 26/50 16/50 f--- 5.44 1.63 (1.00-2.64) B
Deng et al22 12/21 6/22 1.99 2.10 (0.96-4.55) B
Subtotal (95% CI) 71 72 ~ 7.43 1.75 (1.16-2.64)
Total events: 38 (KLT), 22 (Chemotherapy)
Test for heterogeneity: X' =0.30, df = 1 (P =0.59), /' =0%
Test for overall effect: z =2.68 (P = 0.007)
NP + KLT vs NP
An and Yuan" 22/48 24/48 --- I.- 8.15 0.92 (0.60-1.39) BYang et ai'S 9/28 10/29 3.34 0.93 (0.45-1.95) C
Li et al'8 16/36 13/36 - f-- 4.42 1.23 (0.70-2.17) C
Li et al29 9/20 7/20 2.38 1.29 (0.06-2.77) C
Chen et al '6 13/28 9/27 3.11 1.39 (0.72-2.71) C
Lv et al" 11/30 7/30 2.38 1.57 (0.71-3.50) B
Wang and Zhang" 23/39 15/41 f--- 4.97 1.61 (1.00-2.61) C
Wu et al25 26/39 17/44 - 5.43 1.73 (1.12-2.66) CSubtotal (95% CI) 268 275 • 34.18 1.30 (1.07-1.59)Total events: 129 (KLT), 102 (Chemotherapy)
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Figure 2. Meta-analysis forest plot of studies examining the effective rate of kanglalte (KLT) Injection plus chemotherapy versus
chemotherapy alone. (continued)
l'·
en"
l12
P
2' I
t"
l
P
n34 ~
l15
I
p·
1'4
---
l 1+
t ), "
n
ll
ll
fl1
l...
fl1
ll
'1l
f\'I
l
0
f\'I
II
ll
l i i
l
Study
or Subcategory
HEP + KLT VS HEP
Tang"
Subtotal (95% CI)
Total events: 18 (KLT), 12 (Chemotherapy)
Test for heterogeneity: not applicable
Test for overall effect: z =1.02 (P =0.31)
CAP + KLT vs CAP
Lin et al20
Subtotal (95% CI)
Total events: 23 (KLT), 15 (Chemotherapy)
Test for heterogeneity: not applicable
Test for overall effect: z =1.95 (P =0.05)
KLT + NP or GP vs NP or GP
Lu:"
Subtotal (95% CI)
Total events: 27 (KLT). 19 (Chemotherapy)
Test for heterogeneity: not applicable
Test for overall effect: z =0.67 (P =0.50)
KLT + MVP or EP vs MVP or EP
Piao et al12
Subtotal (95% CI)
Total events: 26 (KLT), 13 (Chemotherapy)
Test for heterogeneity: not applicable
Test for overall effect: z =0.51 (P =0.61)
KLT,
n/N
18/26
26
23/39
39
27/62
62
26/214
214
Chemotherapy,
n/N
12/22
22
15/41
41
19/51
51
13/91
91
RR (fixed),
95%CI
Weight,
%
4.42
4.42
4.97
4.97
7.08
7.08
6.20
6.20
RR (fixed),
95%CI
1.27 (0.80-2.01)
1.27 (0.80-2.01)
1.61 (1.00-2.61)
1.61 (1.00-2.61)
1.17 (0.74-1.84)
1.17 (0.74-1.84)
0.85 (0.46-1.58)
0.85 (0.46-1.58)
Quallty*
C
B
C
B
0.1 0.2 0.5 1 2 5 10
Figure 2 (continued). Meta-analysis forest plot of studies examining the effective rate of kanglaite (KLT) injection plus chemo-
therapy versus chemotherapy alone. (continued)
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Figure 2 (continued). Meta-analysis forest plot of studies examining the effective rate of kanglaite (KLT) injection plus chemo-
therapy versus chemotherapy alone. RR =relative risk; MVP =mitomycin + vindesine + cisplatin; GP =gemcitabine hy-
drochloride + cisplatin; NP =vinorelbine + cisplatin; HEP =hydroxycamptothecin + etoposide (VP-16) + cisplatin; CAP =
cyclophosphamide + adriamycin + cisplatin; EP =cisplatin + VP-16; MAP =mitomycin + adriamycin + cisplatin; CEP =
cyclophosphamide + VP-16 + cisplatin. *Per the Cochrane Collaboration,11 the studies were assigned to 1 of the
following 3 categories: A = all quality criteria met, low risk of bias; B = ~1 of the quality criteria only partially
met, moderate risk of bias; C = ~1 of the quality criteria not met, high risk of bias.
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eluded only 1 trial with sample sizes ranging from 39 to 214. These findings may be
due to different chemotherapy regimens being associated with different response rates
or to the sample size being too small to detect a difference.
Three trials15 ,34,35 that did not perform ITT analysis reported that KiT improved
the response rate. Yang et aP5 reported that 3 patients withdrew from the trial group
(2 due to surgery or radiotherapy during the study period and 1 due to financial is-
sues). In addition, 3 patients withdrew from the control group because they had
undergone surgery or radiotherapy during the study. An and Yuan34 reported that
4 patients discontinued therapy due to hearing disorder (2 patients), brain metas-
tasis (1), or hepatic dysfunction (1); another 2 patients died. ] u et aP5 reported
that 10 patients in the KiT group and 6 in the control group were lost to follow-up
due to complete data being unavailable. The results of ITT analysis did not show
statistical differences in the response rate between KiT plus chemotherapy and che-
motherapyalone.
Quality-of-Life Improvement
The details of quality-of-life improvement are shown in Figure 3. Eighteen tri-
als 12,14-20,22-24,26-28,31,32,36,37 reported the number of patients with NSCiC who ex-
hibited an improvement of ~ 10 points in their KPS score. Heterogeneity was found
among subgroups (P < 0.001); therefore, the random effect model was used for total
pooled analysis. Compared with chemotherapy alone, KLT injection plus chemotherapy
was associated with an increase in the number of patients with NSCiC with a
~10-point improvement in their KPS score (RR, 2.05; 95% CI, 1.60-2.64). We ex-
eluded trials with a quality grade of C and conducted a sensitivity analysis, which
revealed concordant results (RR, 3.17; 95% CI, 2.39-4.20).
One study26 found that KiT plus chemotherapy was associated with an increase in
the number of patients with a :2: 1O-point improvement in KPS score. Our meta-analysis
found that there was no statistically significant difference between the 2 groups. We
found that the incorrect statistical method had been used in the study to analyze the
data (ie, the t test was used to analyze dichotomous data).
Two other studies 15 ,18 found that KiT was associated with significant improve-
ment in the KPS score in the absence of ITT analysis. Our ITT analysis showed that
there was no statistically significant difference between the trial and control groups
(Figure 2).
Symptom Improvement
Six trials12,19,27,29,34,36 used improvement in symptoms as an outcome measure and
reported the results. Three trials12,19,36 all used the same symptom improvement scale.
One triaP6 reported the number of patients whose symptoms resolved completely.
Only data from the 3 trials that used the same scale were pooled (Table III). The
pooled analysis showed that KiT plus chemotherapy was associated with improve-
ment in dyspnea and chest pain but not hemoptysis. For the improvement in cough,
the findings from the fixed effect model suggest that KiT injection was effective (RR,
1.36; 95% CI, 1.11-1.67), but those from the random effect model did not find this
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Figure 3. Meta-analysis forest plot of the number of non-small cell lung cancer patients with Karnofsky Performance Status scores
improvement of ~1.0 points of kanglaite (KLT) injection plus chemotherapy versus chemotherapy alone. (continued)
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Figure 3 (continued). Meta-analysis forest plot of the number of non-small cell lung cancer patients with Karnofsky Performance
Status score8 improvement of ~10 points of kanglaite (KLT) Injection plus chemotherapy versus chemotherapy alone.
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Figure 3 (continued). Meta-analysis forest plot of the number of non-small cell lung cancer patients with Karnofsky Performance
Status scores improvement of ~10 points of kanglaite (KLT) injection plus chemotherapy versus chemotherapy alone. RR =
relative risk; MVP = mitomycin + vindesine + cisplatin; EP = cisplatin + etoposide (VP-16); GP = gemcitabine hydrochloride +
cisplatin; NP = vinorelbine + cisplatin; HEP = hydroxycamptothecin + VP-16 + cisplatin; CAP = cyclophosphamide + adriamycin
+ cisplatin; MAP = mitomycin + adriamycin + cisplatin; NIC = vinorelbine + ifosfamide + cisplatin. *Per the Cochrane Collabo-
ration,U the studies were assigned to 1 of the following 3 categories: A = all quality criteria met, low risk of bias; B =
~1 of the quality criteria only partially met, moderate risk of bias; C = ~1 of the quality criteria not met, high risk of bias.
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Table III. Improvement of symptoms associated with kanglaite (KLT) Injection plus chemotherapy versus chemotherapy alone.
Cases, n/N
Treatment Statistical RR
Symptom Group Reference KLT Chemotherapy Model (95%CI)
Cough KLT + MAP/MVP
vs MAP/MVP Liu et al19 49/106 41/98 1.10 (0.81-1.51)
KLT + MVP/EP
vs MVP/EP Piao et al12 118/176 31/78 1.69 (1.26-2.26)
KLT + NIC
vs NIC Zhong et al36 10/22 11/26 1.07 (0.57-2.04)
Total Fixed 1.36 (1.11-1.67)
Random 1.31 (0.95-1.81)
Hemoptysis KLT + MAP/MVP
vs MAP/MVP Liu et al19 29/41 23/34 1.05 (0.77-1.42)
KLT + MVP/EP
vs MVP/EP Piao et al12 45/75 24/53 0.88 (0.65-1.17)
KLT + NIC vs NIC Zhong et al36 14/22 16/26 1.03 (0.67-1.60)
Total Fixed 0.97 (0.80-1.17)
Random 0.97 (0.80-1.17)
Dyspnea KLT + MAP/MVP +
vs MAP/MVP Liu et al19 36/70 15/49 1.68 (1.04-2.71)
KLT + MVP/EP
vs MVP/EP Piao et al12 82/127 19/55 1.87 (1.27-2.75)
KLT + NIC vs NIC Zhong et al36 11/22 8/26 1.63 (0.80-3.31)
Total Fixed 1.77 (1.34-2.33)
Random 1.77 (1.34-2.33) 1<
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Table III (continued). :lIl'I
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Cases, n/N of
Treatment Statistical RR J:l'I
Symptom Group Reference KLT Chemotherapy Model (95 %CI) :lIl>
"Chest pain KLT + EP vs EP Huang et al27 15/53 4/33 2.33 (0.85-6.43) l'Ic
:!
KLT + MAP/MVP n
vs MAP/MVP Liu et al19 50/64 14/47 2.62 (1.66-4.15) ::ul'I
KLT + MVP/EP UlI'll
vs MVP/EP Piao et al12 72/92 9/40 3.48 (1.94-6.24) l>:lI
KLT + NIC vs NIC Zhong et al36 17/22 8/26 2.51 (1.35-4.67)
n
J:
Total Fixed 2.90 (2.11-3.98)
Random 2.81 (2.06-3.84)
Fatigue KLT + MAP/MVP
vs MAP/MVP Liu et al19 51/93 13/69 2.91 (1.71-4.91)
KLT + NP vs NP Li et al29 1/20 7/20 0.14 (0.02-1.06)
Total Random 0.75 (0.04-15.32)
Sensitivity 2.91 (1.72-4.91)
analysis
Anorexia KLT + MAP/MVP
vs MAP/MVP Liu et al19 33/78 18/67 1.57 (0.98-2.53)
KLT + MVP/EP
vs MVP/EP Piao et al12 104/165 19/70 2.32 (1.55-3.47)
KLT + NP vs NP Li et al29 2/20 8/20 0.25 (0.06-1.03)
Total Random 1.33 (0.62-2.86)
Sensitivity 2.91 (1.72-4.91)
analysis
RR = relative risk; MAP = mitomycin + adriamycin + cisplatin; MVP = mitomycin + vindesine + cisplatin; EP = cisplatin + etoposide; NIC = vinorelbine +
ifosfamide + cisplatin; NP = vinorelbine + cisplatin.
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effective (RR, 1.31; 95% CI, 0.95-1.81). Sensitivity analysis s' ;gested that KiT was
effective (RR, 1.40; 95 % CI, 1.13-1.73). Therefore, KiT plus chemotherapy was
considered to be effective in improving cough. One trial36 also found that KiT in-
jection plus chemotherapy was not associated with the complete resolution of
symptoms.
For improvement in fatigue and anorexia, heterogeneity was found among trials;
therefore, only the random effect model was used. Pooled analysis showed that KiT +
chemotherapy was not effective in improving fatigue or anorexia, whereas sensitivity
analysis demonstrated contrary results for both fatigue and anorexia (both, RR, 2.91;
95% CI, 1.72-4.91). Therefore, we considered that KLT was effective in improving
fatigue and anorexia (Table III).
Adverse Events
The details of the AEs are shown in Table IV.
Bone Marrow Suppression
Eight trials15 ,18,23,25,32,34,35,37 did not report the results with regard to leukopenia.
Three trials14,30,35 reported that the leukopenia rate did not meet the WHO grading
criteria8 for acute and subacute toxicity of anticancer drugs. Three trials I7 ,22,23 re-
ported only the total incidence of bone marrow suppression. Thus we could not ex-
tract quantitative data. Twelve trials I2,13.16,19-21.26-30,33 reported the incidence of
grade II to IV leukopenia. The pooled results of those 12 trials suggested that KiT
injection plus chemotherapy was associated with a reduction in the incidence of leu-
kopenia in both the fixed (RR, 0.29; 95% CI, 0.22-0.39) and random effect models
(RR, 0.33; 95% CI, 0.22-0.48). Grade C trials were eliminated for the sensitivity
analysis; the results of sensitivity analysis were in agreement with these results (RR,
0.19; 95% CI, 0.11-0.34).
A total of 11 trials I4,15,18,24,26,28,29,31,32,36,37 did not report their findings with re-
gard to anemia. Six trialsI7.22.23,25.34.35 reported bone marrow suppression findings but
not anemia. The quantitative data of 8 trials I2 .16,19-21,30,31,33 were extracted and a
pooled analysis was conducted. No heterogeneity was found among the subgroups.
The pooled results found that KLT plus chemotherapy was associated with a reduction
in the incidence of grade II to IV anemia in both the fixed (RR, 0.54; 95% CI,
0.42-0.70) and random effect models (RR, 0.55; 95% CI, 0.40-0.76). The results of
the sensitivity analysis were in agreement with this result (RR, 0.56; 95% CI,
0.43-0.72).
Seven trials 15 ,17,22,23,25,34,35 reported bone marrow suppression findings but not
thrombocytopenia. Fourteen trials14,15,18,20,24,26,28-33,36,37 did not report observations
regarding thrombocytopenia. Four trials I2,13,16,19 reported the incidence of grade II to
IV thrombocytopenia. These 4 trials were pooled; KiT plus chemotherapy was associ-
ated with a reduction in the incidence of thrombocytopenia in both the fixed (RR,
0.39; 95% CI, 0.21-0.71) and the random effect models (RR, 0.40; 95% CI, 0.21-
0.78). A sensitivity analysis was in agreement with this result (RR, 0.34; 95% CI,
0.17-0.67).
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~ Table IV. Adverse events associated with kanglaite (KLT) injection plus chemotherapy versus chemotherapy alone.
:II
:II
/II
Z
Cases. n/N of
-tStatistical RR J:
Adverse Event Subgroup Reference KLT Chemotherapy Model (95% CI) /II:II
>
Li and Wang14 "Nausea/ KLT + MVP 11/34 25/30 0.39 (0.23-0.65) /IIc:
vomiting vs MVP of
(grade II-IV) KLT + EP vs EP Huang et al27 3/53 6/33 0.31 (0.08-1.16) n
:II
KLT + GP vs GP Lian et al21 0/50 0/50 - /II
KLT + NP vs NP Wang and Zhang33 5/39 10/41 0.53 (0.20-1.40)
(Il
/II
>
Li et al28 11/36 25/36 0.44 (0.26-0.75) :IIn
Subtotal Fixed 0.46 (0.35-0.59) J:
Random 0.45 (0.35-0.59)
KLT + HEP vs HEP Tang17 6/26 6/22 0.85 (0.32-2.25)
KLT + CAP vs CAP Lin et al20 1/39 4/41 0.26 (0.03-2.25)
KLT + NP or GP LU23 18/62 31/51 0.48 (0.31-0.75)
vs NP or GP
KLT + CEP vs CEP Liu et al30 0/32 0/32
Total Fixed 0.44 (0.34-0.57)
Random 0.44 (0.35-0.57)
Leukopenia KLT + MVP vs MVP Wu et al26 1/21 6/19 0.15 (0.02-1.41)
(grade II-IV) Chu et al13 4/40 7/32 0.46 (0.15-1.43)
Subtotal Fixed 0.32 (0.12-0.85)
Random 0.35 (0.13-0.94)
KLT + EP vs EP Huang et al27 11/53 18/33 0.38 (0.21-0.70)
KLT + NP vs NP Li et al28 6/36 20/36 0.30 (0.14-0.66)
Wang and Zhang33 2/30 6/30 0.33 (0.07-1.52)
Li et al29 4/20 7/20 0.57 (0.20-1.65)
Chen et al16 9/28 14/27 0.62 (0.32-1.19)
Subtotal Fixed 0.44 (0.29-0.68)
Random 0.47 (0.30-0.72)
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Table IV (continued).
Cases, n/N
Statistical RR
Adverse Event Subgroup Reference KLT Chemotherapy Model (95% CI)
Leukopenia KLT + CAP vs CAP Lin et al20 4/39 12/41 0.35 (0.12-0.99)
(grade II-IV) KLT + MVP or Piao et al12 0/214 6/91 0.03 (0.00-0.58)
(cont'd) EP vs MVP or EP
KLT + MAP or Liu et al19 4/131 32/111 0.11 (0.04-0.29)
MVP vs MAP
or MVP
KLT + CEP vs CEP Liu et al30 2/32 13/32 0.15 (0.04-0.63)
KLT + GP vs GP Lian et al21 1/50 2/50 0.50 (0.05-5.34)
Total Fixed 0.29 (0.22-0.39)
Random 0.33 (0.22-0.48)
Anemia KLT + MVP or Piao et al12 10/214 14/91 0.30 (0.14-0.66)
(grade II-IV) EP vs MVP or EP
KLT + MVP vs MVP Chu et al13 4/40 5/32 0.64 (0.19-2.19)
KLT + GP vs GP Lian et al21 0/50 3/50 0.14 (0.01-2.70)
KLT + NP vs NP Wang and Zhang33 0/30 2/30 0.20 (0.01-4.00)
Chen et al16 1/28 2/27 0.48 (0.05-5.01)
Subtotal Fixed 0.33 (0.05-2.01)
Random 0.35 (0.05-2.18)
KLT + CAP vs CAP Lin et al20 1/39 6/41 0.18 (0.02-1.39)
KLT + MVP or MAP Liu et al19 49/131 61/111 0.68 (0.52-0.90)
vs MVP or MAP
KLT + CEP vs CEP Liu et al30 1/32 3/32 0.33 (0.04-3.04)
Total Fixed 0.54 (0.42-0.70) ?<
Random 0.55 (0.40-0.76)
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1'1
Z
Cases, n/N oj
Statistical RR -IJ:
Adverse Event Subgroup Reference KLT Chemotherapy Model (95% CI) !I\:II
l>
Thrombocytopenia KLT + MVP or EP Piao et al12 2/214 5/91 0.17 (0.03-0.86)
..
1'1
C
(grade II-IV) vs MVP or EP oj
KLT + MVP vs MVP Chu et al13 1/40 5/32 0.16 (0.02-1.30 0
KLT + NP vs NP Chen et al16 3/28 3/27 0.96 (0.21-4.37)
;a
1'1
KLT + MAP or MVP Liu et al19 8/131 15/111 0.45 (0.20-1.03) III!I\
vs MAP or MVP l>:II
Total Fixed 0.39 (0.21-0.71) nJ:
Random 0.40 (0.21-0.78)
Phlebitis KLT + EP vs EP Wu et al26 2/21 0/19 4.55 (0.23-89.08)
(grade II-IV) KLT + HEP vs HEP Tang17 2/26 0/22 4.26 (0.22-84.28)
KLT + CAP vs CAP Lin et al20 0/39 0/41
KLT + NP vs NP Wang and Zhang33 1/39 0/41 3.15 (0.13-75.08)
KLT + GP vs GP Deng et al22 9/21 3/22 3.14 (0.98-10.04)
Total Fixed 3.44 (1.30-9.15)
Random 3.38 (1.28-8.89)
Hepatic KLT + GP vs GP Lian et al21 4/50 9/50 0.44 (0.15-1.35)
dysfunction KLT + CAP vs CAP Lin et al20 0/39 0/41
KLT + NP vs NP Wang and Zhang33 0/30 0/30
KLT + MVP or EP Piao et al12 0/214 0/91
vs MVP or EP
Total Fixed 0.44 (0.15-1.35)
Random 0.44 (0.24-0.81)
Renal KLT + GP vs GP Lian et al21 0/50 0/50
dysfunction KLT + CAP vs CAP Lin et al20 0/39 0/41
KLT + NP vs NP Wang and Zhang33 0/30 0/30
RR = relative risk; MVP = mitomycin + vindesine + cisplatin; EP = cisplatin + etoposide (VP-16); GP = gemcitabine hydrochloride + cisplatin; NP =
vinorelbine + cisplatin; HEP = hydroxycamptothecin + VP-16 + cisplatin; CAP = cyclophosphamide + adriamycin + cisplatin; CEP = cyclophosphamide +
epirubicin + cisplatin; MAP = mitomycin + adriamycin + cisplatin.
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Nausea and Vomiting
Nine trials14,17,20,21,23,27,28,30,33 reported the number of patients with grade II to IV
nausea and vomiting. There was no statistical difference among the trials with regard
to heterogeneity. Pooled analysis found that, compared with chemotherapy alone,
KLT injection plus chemotherapy was associated with a reduction in the incidence of
nausea and vomiting in both the fixed (RR, 0.44; 95% CI, 0.34-0.57) and random
effect models (RR, 0.44; 95% CI, 0.35-0.57); however, sensitivity analysis suggested
contradictory results (RR, 0.26; 95% CI, 0.03-2.25). Therefore, there was no statisti-
cal difference between KLT plus chemotherapy and chemotherapy alone with regard
to improvement in nausea and vomiting. Deng et al22 reported that 8 of 21 patients
(38%) receiving KLT plus chemotherapy and 15 of 22 patients (68%) receiving che-
motherapy alone expetienced nausea and vomiting; however, they did not report the
incidence of grade II to IV events.
Phlebitis
Pooled analysis of 4 trials I7 ,22,26,33 found a statistical difference in the incidence of
phlebitis between KLT plus chemotherapy and chemotherapy alone in both the fixed
(RR, 3.44; 95% CI, 1.30-9.15) and random effect models (RR, 3.38; 95% CI,
1.28-8.89). Piao et aP2 reported slight phlebitis in 10 patients that did not require
treatment. Chu et al l3 reported slight phlebitis that could be avoided by IV infusion
of KLT through subclavian vein puncture and catheterization. Yang et all) reported
that phlebitis occurred occasionally prior to 1999; however, after 1999 phlebitis was
not observed due to the use of catheterization. Liu et aP9 reported that 11 patients
discontinued treatment due to severe phlebitis induced by low-quality raw materials
used in the KiT injection. Chen31 andJu et aI35 reported that phlebitis occurred only
occasionally. Lin et al20 and Li et al29 reported no incidence of phlebitis. The 14 other
trials14,l6,18,2l,23-25,27,28,30,32,34,36,37 did not mention phlebitis.
Hepatic and Renal Dysfunction
Pooled analysis of 4 trials l2 ,20,21,33 using the fixed model found that KiT plus
chemotherapy did not decrease the incidence of grade II to IV hepatic dysfunction
(RR, 0.44; 95% CI, 0.15-1.35). Five trials12,20,31,33,35 reported no incidence of grade
II to IV hepatic dysfunction. Fourteen trials15- 19, 23-25,27,30,32,34,36,37 did not mention
hepatic dysfunction. Li and Wang 14 and Deng et al22 reported the incidence of hepatic
dysfunction but not specifically the incidence of grade II to IV events.
Three rrials20,21,33 reported no incidence of grade II to IV renal dysfunction. Li and
Wang 14 teported that 5 patients in the KLT plus chemotherapy group and 22 patients
in the chemotherapy alone group experienced renal dysfunction, bur the incidence of
grade II to IV events was not reported. Deng et aF2 reported the incidence of renal
dysfunction but not specifically the incidence of grade II to IV events.
DISCUSSION
KLT injection is a product of traditional Chinese medicine; however, its effectiveness
and safety in patients with NSCLC have been tested using Western methodology.3
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Several controlled trials of KLT injection plus chemotherapy versus chemotherapy
alone have been conducted in both Asian and American populations. However, be-
cause we included only RCTs, no RCTs of US populations were identified.
In total, this meta-analysis found KLT injection plus chemotherapy improved the
response rate in these patients with NSCLC (RR, 1.34; 95% CI, 1.19-1.51). The
subgroups ofdifferent chemotherapy regimens led to different conclusions. Subgroups
of HEP, CAP, CEP, NP/GP, and MVP/MAP chemotherapy regimens included only
1 trial each; therefore, no statistical differences were found between the KLT plus
chemotherapy and chemotherapy alone groups. On the other hand, the subgroups of
MVP, GP, and NP regimens included> 1 trial; statistical differences were found be-
tween the 2 groups. Therefore, it is possible that the sample size of a single trial was
too small to test validity.
The effectiveness of KLT plus chemotherapy in improving the quality of life of
patients with NSCLC was found to be highly significant (RR, 2.05; 95% CI,
1.60-2.64). Two trials 1S ,18 found positive conclusions, but the results of ITT analysis
in our meta-analysis were negative, suggesting that the loss of patients to follow-up
affected the results to some extent. One trial26 concluded positive results by using
inappropriate statistical methods, bur the findings of our meta-analysis were negative.
Therefore, the statistical method used was also a factor influencing the results.
KLT plus chemotherapy in this meta-analysis was associated with a significant
decrease in the incidence of AEs, including grade II to IV leukopenia, anemia, and
thrombocytopenia. This combination therapy was also associated with significant
improvement in the symptoms of grade II to IV cough, dyspnea, chest pain, fatigue,
and anorexia.
KLT injection plus chemotherapy was not associated with obvious toxicity or AEs.
Some patients may experience nausea, low-grade fever, or occasional skin rash or
phlebi tis. 12-14, 16,17,19-21 ,23,26-30,33 No significant hepatic or renal dysfunction was
found in either KLT injection plus chemotherapy or chemotherapy alone group.
LIMITATIONS
Literature related to KLT therapy in patients with NSCLC was collected by manual
and Internet search and by requesting data from pharmaceutical manufacturers. A
formal data extraction table was designed to extract data for quantitative analysis. The
accuracy of the data extraction was assessed using a second reviewer. The 26 trials
included were all published in China. They included 2209 patients with NSCLC. The
sample size of each trial varied from 40 to 305 patients. None of the trials had sample
sizes determined a priori. The heterogeneity among subgroups might be attributed to
differing sample sizes. We found that the positive effect increased with a bigger
sample size.
Information about random sequence generation was available for only 10 tri-
als,12,13,18-24,35 while information about allocation concealment was not available for
any of the included trials. Therefore, there was a high risk of selection bias and
performance bias in this systematic review. Information about blinding was avail-
able for only 3 trials I2 ,13,3S; therefore, a high detection bias also existed in this sys-
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tematic review. Only 6 trials12 ,13,15,18,19,35 reported the number ofpatients who were lost
to follow-up or the reasons they were lost to follow-up. Our ITT analysis reversed the
original positive results in the case of 3 trials 15 ,25,35 that reported the response rate and
2 trials14,17 that reported improvement in quality of life. In the other trials that did not
report the status of loss to follow-up or withdrawal, a high withdrawal bias existed.
Only 4 trials12,19,27,36 reported improvement of symptoms, including cough, hemop-
tysis, dyspnea, chest pain, fatigue, and anorexia. Overall, 11 trials14,16,17,20,21,23,27-30,33 re-
ported AEs occurring in the trial and control groups. The remaining 15 trials did not
provide information about AEs. Four trials12 ,19,27,36 reported the outcome of symptom
improvement. Only 3 trials 17 ,22,23 reported the total incidence of bone marrow sup-
pression. No data on leukopenia, anemia, or thrombocytopenia were available. Selec-
tion reporting outcome bias led to some unavailability of integrated results. No trial
reported the outcome measure of mortality. These conclusions are also limited by the
low quality scores of the included trials.
CONCLUSION
This meta-analysis found that, compared with chemotherapy alone, KLT injection
plus chemotherapy improved the response rate, quality of life, and symptoms, and
decreased the incidence of AEs in these patients with primary NSCLC.
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